2024">Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy
ESMO Gastrointestinal Oncology,
2022">Predictions of overall survival (OS) and progression-free survival (PFS) for specific therapeutic interventions in newly diagnosed glioblastoma multiforme (GBM) using Cellworks Singula: myCare-024-04
ASCO Meeting Library,
2022">Cellworks Singula therapy response index (TRI) predicts clinical outcomes for esophageal adenocarcinoma: myCare-004